Physician profile
David Shaker
NPI 1396130365
$33,986.17
in general payments reported to CMS, 2019-2025
50 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $480 · 2021: $600 · 2022: $468 · 2023: $973 · 2024: $1,192 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $3,283 · Travel and Lodging: $685 · Education: $46.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,300.00 |
| Food and Beverage | $3,283.29 |
| Travel and Lodging | $685.44 |
| Education | $46.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28,701.61 | 2020-2025 | Zepbound, Mounjaro, Trulicity |
| Novo Nordisk INC | $1,108.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $875.58 | 2022-2025 | Aveir, Gallant, Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $384.80 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Amgen INC. | $381.35 | 2019-2025 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $174.56 | 2019-2025 | |
| Abbvie INC. | $172.56 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $171.52 | 2019-2025 | Trelegy Ellipta |
| Boston Scientific Corporation | $149.75 | 2019-2023 | Emblem Mri S-Icd |
| Amarin Pharma, INC. | $146.38 | 2019-2021 | |
| Medtronic Vascular, INC. | $145.52 | 2019-2020 | |
| Genzyme Corporation | $127.88 | 2023 | |
| Janssen Pharmaceuticals, INC | $121.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $103.58 | 2021-2024 | |
| Integra Lifesciences Corporation | $92.73 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.